Official Guidance to Facilitate Clinical Trials during COVID-19 pandemic
The European Commission has published an official Guidance on The Management of Clinical Trials During COVID-19 Pandemic. This guidance aims to ensure that clinical trials can continue to take place in the EU during the COVID-19 pandemic. The aim is to mitigate the disruption of clinical research in Europe and therefore the negative effects of the pandemic, without compromising on quality and safety. These recommendations are an important part of the overall strategy in finding treatments and a vaccine to protect citizens against the coronavirus.
With more than 200 coronavirus clinical trials now registered in the EU database, the guidance offers recommendations for simple and flexible measures to respond to the current situation, and to ensure that patients participating in clinical trials across the EU can continue receiving their medicines.
The official guidance can be accessed by clicking here. To know more about this official guidance, please click here. © European Union, 1995-2020
To discuss about this subject in the COVID-19 Forum, please follow this link.
